Fc receptor like BGenealiases: FCRL2 · FCRLM2 · FCRLY · FREB-2 · FREB2 · FcRY
Q-omics provides the consensus-scored FCRLB profile across patient tissues and cancer cell-line models. FCRLB expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FCRLB is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, FCRLB RNA expression shows 16,612 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where FCRLB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCRLB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCRLB survival associations across molecular data types. FCRLB RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCRLB RNA expression–survival associations across cancer types. High FCRLB expression shows unfavorable associations in ACC, THCA, COAD, LUAD, GBM and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FCRLB RNA expression.
This table summarizes FCRLB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FCRLB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCRLB shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, BLCA, KIRP and BRCA. The HNSC box plot shows higher FCRLB RNA expression in tumor versus normal tissue (log2 FC = +0.679, t-test p < 0.001).
This table shows molecular features associated with FCRLB in patient tissues and cancer cell lines. In patient samples, FCRLB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FCRLB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
